Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hannah M. Canepa

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Smoking Status and Self-Reported Race Affect the Frequency of Clinically Relevant Oncogenic Alterations in Non-Small-Cell Lung Cancers at a United States-Based Academic Medical Practice

English

Related publications

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy

English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

Oncology

2015

English

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

Journal of Investigative Dermatology

English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology

Oncology

2012

English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology

Oncology

2012

English

HGF Induces Novel EGFR Functions Involved in Resistance Formation to Tyrosine Kinase Inhibitors

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hannah M. Canepa

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Smoking Status and Self-Reported Race Affect the Frequency of Clinically Relevant Oncogenic Alterations in Non-Small-Cell Lung Cancers at a United States-Based Academic Medical Practice

Related publications

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

HGF Induces Novel EGFR Functions Involved in Resistance Formation to Tyrosine Kinase Inhibitors